Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum94046Research ArticleKlinicheskie i farmakoekonomicheskie aspekty terapii serdechnoy nedostatochnosti selektivnym antagonistom al'dosterona eplerenonomRudakovaA. V-MoiseevaO. M-15052014165475028122021Copyright © 2014, Consilium Medicum2014хроническая сердечная недостаточностьинфаркт миокардаремоделированиесократительная способностьантагонист альдостеронаэплеренонлетальность[Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. и др. Современный образ пациента с ХСН в европейской части Российской Федерации (госпитальный этап). Сердечная недостаточность. 2011; 5.][Lloyd-Jones D, Adams R.J, Brown T.M et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 2010; 121: e46-215.][Yousef Z.R, Redwood S.R, Marber M.S. Postinfarction left ventricular remodelling: where are the theories and trials leading us? Heart 2000; 83: 76-80.][Bolognese L, Neskovic A, Parodi G et al. Left Ventricular Remodeling After Primary Coronary Angioplasty Patterns of Left Ventricular Dilation and Long-Term Prognostic Implications. Circulation 2002; 106: 2351-7.][Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100 000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation 1998; 97: 2202-12.][Latini R, Tognoni G, Maggioni A.P et al. Clinical effects of early angiotensin - converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96 712 randomized patients. Angiotensin - converting Enzyme Inhibitor Myocardial Infarction Collaborative Group. J Am Coll Cardiol 2000; 35 (7): 1801-7.][Rodrigues E.J, Eisenberg M.J, Pilote L. Effects of early and late administration of angiotensin - converting enzyme inhibitors on mortality after myocardial infarction. Am J Med 2003; 115 (6): 473-9.][Exner D.V, Dries D.L, Waclawiw M.A et al. Beta - adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction. J Am Coll Cardiol 1999; 33 (4): 916-23.][Vantrimpont P, Rouleau J.L, Wun C.C et al. SAVE Investigators Additive beneficial effects of beta - blockers to angiotensin - converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. J Am Coll Cardiol 1997; 29 (2): 229-36.][Baker W.L, Coleman C.I, Kluger J et al. Systematic review: comparative effectiveness of angiotensin - converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. Ann Intern Med 2009. Published online ahead of print.][Mc Kelvie R.S, Yusuf S, Pericak D et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056-64.][The RESOLVD Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation 2000; 101: 378-84.][Pitt B, Zannad F, Remme W.J et al. The effect of spironolactone on morbidity andmortality in patients with severe heart failure. New Engl J Med 1999; 341 (10): 709-17.][Juurlink D.N, Mamdani M.M, Lee D.S et al. Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543-51.][Pitt B, White Н, Nicolau J et al. Eplerenone Reduces Mortality 30 Days After Randomization Following Acute Myocardial Infarction in Patients With Left Ventricular Systolic Dysfunction and Heart Failure. J Am Coll Cardiol 2005; 46: 425-31.][Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21.][Рудакова А.В., Моисеева О.М. Эффективность затрат при терапии селективным антагонистом альдостерона эплереноном больных с сердечной недостаточностью. Артериальная гипертензия. 2012; 18 (2): 108-17.][World Health Organization. Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. Geneva (Switzerland): World Health Organization 2001.][Mc Kenna C, Burch J, Suekarran S et al. A systematic review and economic evaluation of the clinical effectiveness and cost - effectiveness of aldosterone antagonists for postmyocardial infarction heart failure. Health Technol Assess 2010; 14 (24).][De Pouvourville G, Solesseb A, Beillat M. Cost - effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: The EPHESUS study. Arch Cardiovasc Dis 2008; 101: 515-21.][Weintraub W, Zhang Z, Mahoney E et al. Cost-Effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation 2005; 111: 1106-13.][Croom K, Plosker G. Eplerenone: a pharmacoeconomic review of its use in patients with post - myocardial infarction heart failure. Pharmacoeconomics 2005; 23 (10): 1057-72.][Szucs T, Holm M, Schwenkglenks M et al. Cost - effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction - an analysis of the EPHESUS study from a Swiss perspective. Cardiovasc Drugs Ther 2006; 20 (3): 193-204.][Pitt B, Gheorghiade M, Zannad F et al. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction ≤30%. Eur J Heart Failure 2006; 8: 295-301.][Zannad F, Mc Murray J.J.V, Krum H et al. EMPHASIS-HF Study Group Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.][Krum H, Shi H, Pitt B et al. Clinical Benefit of Eplerenone in Patients With Mild Symptoms of Systolic Heart Failure Already Receiving Optimal Best Practice Background Drug Therapy: Analysis of the EMPHASIS-HF Study. Circ Heart Fail 2013; 6: 711-8.][Collier T, Pocock S, Mc Murray J et al. The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. Eur Heart J 2013; 34: 2823-9.][Swedberg K, Zannad F, Mc Murray J.J et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol 2012; 59 (18): 1598-603.][Girerd N, Collier T, Pocock S et al. Clinical benefits of Eplerenone in patients with systolic NYHA II heart failure when initiated shortly after hospital discharge. Eur Heart J 2013; 34: P3304.]